Patricia A. Ganz, MD, of the University of California at Los Angeles, discusses the limited sensitivity and specificity of surveillance testing for cancer recurrence and finding a better way to reassure patients about their continuing care.
Tim A. Ahles, PhD, of Memorial Sloan Kettering Cancer Center, discusses “chemobrain” and what can be done to help patients cope with this symptom.
Kevin C. Oeffinger, MD, of Memorial Sloan Kettering Cancer Center, summarizes the main take-home messages of the conference.
Kerri M. Winters-Stone, PhD, of Oregon Health and Science University, discusses the results of her study, which showed that, years after treatment, nearly half of women cancer survivors still have symptoms of chemotherapy-induced peripheral neuropathy. The findings may inform rehabilitative programs to prevent falls and injuries (Abstract 130).
Dana Barnea, MD, of Memorial Sloan Kettering Cancer Center, discusses data that suggest annual palpation of the thyroid is an adequate and safe means of screening childhood and young adult cancer survivors, a population at high risk for this type of cancer (Abstract 254).
Tara O. Henderson, MD, MPH, of the University of Chicago, summarizes a session on the multidisciplinary approaches to survivors with medical needs beyond cancer treatment.
